October 21, 2016 SBI Biotech Co., Ltd.

SBI Biotech's Licensed Product, an Anti-ILT7 Antibody (MEDI7734*) Has Achieved a Developmental Milestone in a Phase I Clinical Trial

SBI Biotech Co., Ltd. (Head office: Minato-ku, Tokyo; President: Takeshi Irie; "SBI Biotech") hereby announces that MedImmune (Head office: Gaithersburg, Md., USA), the global biologics research and development arm of AstraZeneca and the licensee, has started to dose patients with an anti-ILT7 antibody (MEDI7734*) ina Phase I Clinical Trial.

SBI Biotech and MedImmune entered into a licensing and collaboration agreement in September of 2008 to develop an antibody to the ILT7 antigen. Under the term of this agreement, SBI Biotech will now receive a milestone payment.

* MEDI7734 is MedImmune's development code for the Anti-ILT7 antibody.

About the anti-ILT7 antibody (MEDI7734)

ILT7 is a cell surface protein expressed on plasmacytoid dendritic cells (pDCs). The anti-ILT7 antibody (MEDI7734) has potential in treating autoimmune diseases.

******************************************************************************* For further information, please contact:

SBI Biotech Co., Ltd. Business Planning Division

Phone number: +81-3-6229-0787

SBI Holdings Inc. published this content on 21 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 October 2016 07:48:08 UTC.

Original documenthttp://www.sbigroup.co.jp/english/news/pdf/2016/1021_a_en.pdf

Public permalinkhttp://www.publicnow.com/view/AE7AB232051A4B8AED96795B4B05D03749FB1BF6